Business
Trevi Therapeutics to Participate in Upcoming Investor and Healthcare Events
Two abstracts accepted for oral presentation at the 13th London International Cough Symposium NEW HAVEN, Conn., July 2, 2024 /PRNewswire/ -- Trevi
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Two abstracts accepted for oral presentation at the 13th London International Cough Symposium\nNEW HAVEN, Conn., July 2, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC), today announced that senior management will be attending investor and medical conferences in July and August. In addition, Trevi is pleased to announce that abstracts on the ongoing Phase 2b CORAL and Phase 2a RIVER trials were accepted for presentation at the Thirteenth London International Cough Symposium.\n\n \n \n \n \n \n \n\n \nLeerink Partners Therapeutics Forum: I&I and MetabolismJuly 9-10, 2024, Boston, MATrevi Representatives: Jennifer Good, President and CEO, and Lisa Delfini, CFO\nThe Thirteenth London International Cough SymposiumJuly 18-19, 2024, London, UKAbstract 1: Sample Size Reestimation in an Ongoing Dose-ranging Study of Nalbuphine Extended-release For Cough in Idiopathic Pulmonary Fibrosis (CORAL)Abstract 2: Efficacy And Safety of Nalbuphine Extended-release Tablets for the Treatment of Refractory Chronic Cough: A Phase 2 Trial in Progress (RIVER)Symposium Focus: The Thirteenth London International Cough Symposium brings together clinicians, scientists, and researchers in the field of cough from across the world. The purpose of this symposium is to share, review and discuss emerging ideas, novel approaches, and clinical research advancements in the management of chronic cough. Registration details\nOppenheimer's Biotech in the BerkshiresAugust 5-7, 2024, Lenox, MATrevi Representative: Jennifer Good, President and CEO\nStifel 2024 Biotech Summer SummitAugust 12-14, 2024, Newport RITrevi Representatives: Jennifer Good, President and CEO, and Farrell Simon, CCO\nAbout Trevi Therapeutics, Inc.Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio is a dual ĸ-opioid receptor agonist and µ-opioid receptor antagonist that works both centrally in the brain as well as peripherally in the lungs and has the potential for ...